Tender Details
Beyond this tender, use our platform to source any product, service, or solution.
Get direct quotes or register as a qualified provider.
About Tender
๐ Urgent Tender For Inj. Ranibizumab ๐ The Ministry Of Railways, Specifically The Central Government Ministry/Department, Is Issuing A Tender For The Procurement Of Inj. Ranibizumab, A Critical Ophthalmic Medication. ๐๏ธ The Drug Must Be Dgci Approved For The Treatment Of Diabetic Macular Oedema, Retinal Vein Occlusion, Proliferative Diabetic Retinopathy, Retinopathy Of Prematurity, And Myopic Choroidal Neovascular Membrane. ๐ Bid Submission Deadline: June 25, 2024, 11:30 Am Interested Bidders Must Submit An Earnest Money Deposit (Emd) Of Inr 55,360. No Tender Fee Is Applicable. Detailed Specifications, Pricing, And Delivery Timelines Must Be Included In The Bids. Bidders Should Ensure Compliance With All Relevant Regulations And Guidelines. Keywords: Inj. Ranibizumab, Ophthalmic Medication, Dgci Approved, Ministry Of Railways, Tender, Procurement, Eye Health, Central Govt. Ministry/Department, Emd, Bid Submission| Particulars | Details |
|---|---|
| Title |
Inj. Ranibizumab (Each Pfs/ Amp/Vial Contains Ranibizumab Upto 2.3 Mg/ 0.23 Ml) {The Drug Should Be Dgci Approved For Diabetic Macular Oedema, Retinal Vein Occlusion, Proliferative Diabetic Retinopathy, Retinopathy Of Prematurity And Myopic Choroidal Neovascular Membrane.}
|
| Description |
For Complete Deion And Other Details, Please Refer To Tender
|
| Organisation | Ministry of Railways | Central Govt. Ministry/Department |
| Tender Id | 106355447 |
|
Reference Number |
28241440A |
| Tender Fee | 0 |
| EMD | 55360 |
| Tender Value | - |
| Place | Gorakhpur |
| Link |
View Original Tender Notice
https://www.ireps.gov.in/ireps/supply/pdfdocs/062024/106355447/viewNitPdf_4590880.pdf |
| Start Date | May 31, 2024 20:58 |
| End Date |
Expired
25/06/2024
Expired 840 days ago |
Tender Support
Get help with filing, GeM registration, documents, or relevant tender alerts.
Ranibizumab intra vitreal injection - vial/pfs 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - vial/pfs 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - pfs approved for all indications 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRanibizumab 2.3mg inj approved by cdsco for the following indications- 1) wet amd, 2) diabetic macular edema, 3) retinal vein occlusion, 4) myopic cnvm, 5) proliferative diabetic retinopathy
For complete deion and other details, please refer to tender
Read moreInj. ranibizumabo.23ml, 10mg/ml vial, ra [inj. ranibizumabo.23ml, 10mg/ml vial, ranibizumab biosimilar, the medicine should be approved by dcgi/fda for wet amd, diabetic macular edema, rv0, myopic cnvm ,retinopathy of prematurity and pdr .]
For complete deion and other details, please refer to tender
Read moreRunning contract for inj. ranibizumab (10mg/ml)) (0.23mg/0.23ml) for intravitreal injection vial, the medicine should be approved by dcgi for wet armd, diabetic macular oedema, rvo, myopic cnvm, pdr and rop.
For complete deion and other details, please refer to tender
Read moreRunning contract for inj. ranibizumab (10 mg/ml) (0.23 mg/0.23 ml)for intravitreal injection vial. the medicine should be approved by dcgi for wet armd, diabetic macular oedema, rvo, myopic cnvm, pdr and rop.
For complete deion and other details, please refer to tender
Read moreof your Industry type